- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07561359
12-Week Strength and Functional Exercise Program for Hereditary Spastic Paraplegia Trial (HSPMOVE) (HSPMOVE)
12-Week Strength and Functional Exercise Protocol for Treating Motor Symptoms in Individuals With Hereditary Spastic Paraplegia: Adaptive Randomized Crossover Clinical Trial
This study aims to evaluate whether a 12-week program of strength and functional exercises can improve movement and daily function in people with Hereditary Spastic Paraplegia (HSP). Participants will take part in supervised exercise sessions twice a week, delivered by videoconference, with guidance from a physiotherapist. The exercises will be tailored to each participant's abilities and goals and will focus on improving muscle strength, balance, and walking.
The study is a randomized crossover trial, meaning that all participants will experience both the exercise program and a comparison period without the intervention.
Eligible participants are individuals aged 16 to 70 years with a clinical or genetically confirmed diagnosis of HSP, who are able to walk independently (with or without assistive devices) and have stable treatment for spasticity.
Researchers will measure changes in walking ability, balance, muscle strength, and quality of life using clinical scales and functional tests. These include walking tests, mobility assessments, and questionnaires about daily activities and confidence in movement. To reduce bias, outcome assessments will be performed by an evaluator who is blinded to the participants' group allocation.
The results of this study will help determine whether a structured exercise program is safe, feasible, and effective for improving motor symptoms in people with HSP, and may support its use as part of routine care.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil, 90035-003
- Centro de Pesquisa Clínica do Hospital de Clínicas de Porto Alegre
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Diagnosis of hereditary spastic paraplegia confirmed by genetic testing or clinical diagnosis with a positive family history
- Age between 16 and 70 years
- Independent ambulation, with or without assistive devices
- Access to an electronic device (smartphone, tablet, or computer) with camera and internet connection
- Stable therapeutic regimen for spasticity management (pharmacological and/or physiotherapy) for at least 6 months prior to enrollment
Exclusion Criteria:
- Presence of other neurological or systemic conditions causing additional motor impairment or musculoskeletal injury limiting movement
- Inability to perform performance outcomes even with assistive devices
- Planned or ongoing botulinum toxin injections or surgical interventions for spasticity reduction during the 12-week intervention period
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Individualized Functional and Strength Exercise Intervention
Individualized functional and strength exercise intervention delivered via videoconference and supervised by a physiotherapist.
|
Individualized functional and strength exercise intervention delivered via videoconference and supervised by a physiotherapist.
Exercises are tailored according to Goal Attainment Scaling (GAS) and baseline physical activity level.
The program consists of two sessions per week and follows key training principles (individuality, overload, adaptation, specificity, continuity, reversibility, and variability) with progressive loading.
The intervention focuses on improving lower limb strength and functional mobility, particularly gait, and includes balance and gait training.
Sessions are scheduled with 2-3 day intervals.
Each exercise includes 1-3 sets of 8-15 repetitions, with 30-60 seconds rest between sets.
Training intensity ranges from 40-60% of maximal strength for sedentary participants and 50-70% for physically active participants.
|
|
Sin intervención: No Intervention
No individualized prescription or real-time supervision will be provided during this phase.
They will receive printed educational materials containing general guidance on performing strength and functional exercises.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Spastic Paraplegia Rating Scale (SPRS)
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Clinician-reported outcome used to assess disease severity in hereditary spastic paraplegia (HSP).
It consists of 13 items evaluating gait, lower limb strength and spasticity, joint contractures, pain, and bladder and bowel function.
Total scores range from 0 to 52, with higher scores indicating greater disease severity.
|
Baseline, 12 and 24 weeks
|
|
Timed Up and Go Test (TUG) - maximum walking speed
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Performance outcome in which participants are instructed to stand up from a seated position, walk 3 meters, turn around, walk back, and sit down at maximum walking speed.
The time to complete the task is recorded.
|
Baseline, 12 and 24 weeks
|
|
Goal Attainment Scaling (GAS)
Periodo de tiempo: Baseline, 12 and 24 weeks
|
individualized patient reported outcome measure used to assess the extent to which patient-specific goals are achieved during the intervention.
Each participant will define four main individualized goals at baseline.
Goals and expected levels of performance are defined individually for each participant and scored on a 5-point scale ranging from -2 to +2.
A score of 0 represents the expected level of achievement, positive scores (+1, +2) indicate better-than-expected outcomes, and negative scores (-1, -2) indicate less-than-expected outcomes.
|
Baseline, 12 and 24 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
10-Meter Walk Test (10MWT) - self-selected walking speed
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Performance outcome in which participants will walk at a comfortable, self-selected pace over a 10-meter distance.
A flying start will be used, allowing 2 meters for acceleration and 2 meters for deceleration outside the timed zone.
Walking speed (m/s) is calculated based on the time to complete the central 10-meter distance.
|
Baseline, 12 and 24 weeks
|
|
10-Meter Walk Test (10MWT) - maximum walking speed
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Performance outcome in which participants will walk at maximum walking speed over a 10-meter distance.
A flying start will be used, allowing 2 meters for acceleration and 2 meters for deceleration outside the timed zone.
Walking speed (m/s) is calculated based on the time to complete the central 10-meter distance.
|
Baseline, 12 and 24 weeks
|
|
Timed Up and Go (TUG) - self-selected walking speed
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Performance outcome in which participants are instructed to stand up from a seated position, walk 3 meters, turn around, walk back, and sit down at at a comfortable, self-selected pace .
The time to complete the task is recorded.
|
Baseline, 12 and 24 weeks
|
|
Falls Efficacy scale - International (Brazilian Portuguese)
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Patient-reported outcome used to assess concern about falling during daily activities in community-dwelling individuals.
It consists of 16 items covering functional and participation activities (e.g., sitting/standing from a chair, climbing stairs).
Each item is scored from 1 (not at all concerned) to 4 (very concerned), with total scores ranging from 16 to 64.
Higher scores indicate greater concern about falling.
|
Baseline, 12 and 24 weeks
|
|
36-Item Short Form Health Survey (SF-36) - Brazillian Portuguese
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Generic, patient-reported outcome of health-related quality of life.
It consists of 36 items covering multiple domains, including physical functioning, role limitations due to physical health, pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health.
Scores range from 0 to 100, with higher scores indicating better overall health status.
|
Baseline, 12 and 24 weeks
|
|
Medical Research Council (MRC) Muscle Strength Scale
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Clinician-reported outcome of muscle strength, graded from 0 (no contraction) to 5 (normal strength).
Lower limb muscle groups assessed include hip flexors and extensors, hip abductors and adductors, knee flexors and extensors, and ankle dorsiflexors and plantarflexors.
|
Baseline, 12 and 24 weeks
|
|
Modified Ashworth Scale (MAS)
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Clinician-reported outcome used to assess resistance to passive movement and muscle tone.
It is scored on a 5-point scale from 0 (normal muscle tone) to 4 (rigid in flexion or extension).
In this study, it will be applied to the hip adductor and knee flexor muscles to assess lower limb spasticity.
|
Baseline, 12 and 24 weeks
|
|
Patient Global Impression of Change (PGI-C)
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Patient-reported outcome measuring perceived overall improvement or worsening following the intervention.
It is a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), capturing the patient's global assessment of change.
|
Baseline, 12 and 24 weeks
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Handheld Dynamometry (microFET2)
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Digital health technology in which muscle strength will be assessed using a handheld dynamometer (microFET2) to measure peak force output in lower limb muscle groups including hip flexors and extensors, hip abductors and adductors, knee flexors and extensors, and ankle dorsiflexors and plantarflexors.
This provides an objective, quantitative measure of muscle strength (expressed in kgf) for comparison with clinical scales.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Timed Up and Go test
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Sit-to-stand, turning, and stand-to-sit times in seconds (1 decimal) will be recorded during and Timed Up and Go (TUG) test at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Cadence
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Cadence in steps/min will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Elevation Midswing, Lateral Step Variability, Circumduction
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Elevation Midswing, Lateral Step Variability, Circumduction in cm will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Gait Cycle Duration, Step Duration
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Gait Cycle Duration and Step Duration in seconds will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Gait Speed
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Gait Speed in m/s will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Stride Length
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Stride Length in meters will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Foot Strike Angle, Toe Off Angle, Toe Out Angle, Lumbar Coronal (RoM), Lumbar Sagittal (RoM), Lumbar Transverse (RoM), Trunk Coronal (RoM), Trunk Sagittal (RoM), Trunk Transverse (RoM)
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Foot Strike Angle, Toe Off Angle, Toe Out Angle, Lumbar Coronal (RoM), Lumbar Sagittal (RoM), Lumbar Transverse (RoM), Trunk Coronal (RoM), Trunk Sagittal (RoM), Trunk Transverse (RoM) in ° degrees will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Double Support, Single Limb Support, Stance, Swing, Terminal Double Support
Periodo de tiempo: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Double Support, Single Limb Support, Stance, Swing, Terminal Double Support in Gait Cycle Time (%) will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Nervioso
- Enfermedades Neuromusculares
- Enfermedades Genéticas Congénitas
- Enfermedades del Sistema Nervioso Periférico
- Enfermedades neurodegenerativas
- Anomalías congénitas
- Trastornos Heredodegenerativos, Sistema Nervioso
- Malformaciones del Sistema Nervioso
- Polineuropatías
- Neuropatía sensorial y motora hereditaria
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Comportamiento
- Paraplejía Espástica, Hereditaria
- Actividad del motor
Otros números de identificación del estudio
- 2023-0040
- CAAE: 67528023.6.0000.5327 (Otro identificador: CEP-HCPA)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .